Breaking Finance News

A statement released earlier today by Roth Capital about Zafgen (NASDAQ:ZFGN) bumps the target price to $9.00

Yesterday Zafgen (NASDAQ:ZFGN) traded 2.76% higher at $4.90. The company’s 50-day moving average is $4.54 and its 200-day moving average is $3.86. The last stock close price is up 30.62% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 176,870 shares of the stock were exchanged, up from an average trading volume of 166,576

In a report released on 4/20/2017 Roth Capital increased the stock price target of Zafgen (NASDAQ:ZFGN) to $9.00 indicating a possible upside of 0.84%.

Previously on 1/12/2017, Zacks Investment Research reported about Zafgen (NASDAQ:ZFGN) raised the target price from $0.00 to $4.50. At the time, this indicated a possible upside of 0.14%.

See Chart Below


Zafgen has a 52 week low of $2.89 and a 52 week high of $7.73 The company’s market cap is currently $0.

In addition to Roth Capital reporting its target price, a total of 7 firms have issued a report on the stock. The consensus target price is $22.14 with 2 firms rating the stock a strong buy, 2 firms rating the stock a buy, 3 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Zafgen (NASDAQ:ZFGN)

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.